We are confident the Urologix social media presence will provide information that sparks much needed discussion with and between patients.
Minneapolis, MN (PRWEB) April 15, 2013
Urologix, Inc. (NASDAQ:ULGX), the leading provider of in-office BPH therapy, has launched a comprehensive social media campaign for patients and clinicians alike. A new Facebook page and blog will disseminate useful news and information on the treatment of BPH also known as Enlarged Prostate; a condition that affects many men over the age of 50. These two social media platforms add to Urologix’s existing internet presence on YouTube, LinkedIn and its recently relaunched website.
While not life-threatening, BPH symptoms can have a significant impact on a man’s quality of life, interfering in the lives of both the sufferer and those around him. The persistent urge to urinate and frequent waking at night can be troublesome and exhausting. Today, BPH medication is the most common treatment option for patients. However, while medication is effective for some patients, it can cause significant side effects and does not always adequately relieve BPH symptoms.
Urologix offers two non-surgical, office-based therapies, Cooled ThermoTherapyTM (Transurethral Microwave Therapy - TUMT) and Prostiva® RF Therapy (Transurethral Needle Ablation - TUNA) to patients with moderate to severe BPH as an alternative to long-term BPH drug utilization. Many Cooled ThermoTherapy and Prostiva patients experience durable and significant symptom improvement. These clinically proven results typically last at least five years and the majority of patients experience few or no side effects.* In-office, non-surgical BPH therapies are included in the American Urology Association’s guidelines for the diagnosis and treatment of BPH.
“We are confident the Urologix social media presence will provide information that sparks much needed discussion with and between patients. Oftentimes, men with BPH will suffer silently with the disease because they aren’t aware there are solutions outside of drugs and surgery. “ said Greg Fluet, Chief Executive Officer of Urologix. “Social Media is a great way to provide timely and relevant information to help educate patients on these proven treatment options for BPH.“
The Urologix social media presence will complement an already comprehensive website, offering patients useful and interactive tools to help identify, manage and find help for their condition. Patients can currently find a urologist, check their BPH symptom score, view an online seminar, and hear from patients who have undergone in-office BPH treatment.
If you are interested in learning more about BPH and non-surgical treatment options, become a fan of Urologix on Facebook, check out their website including their latest blog entry, and watch for informative videos on their YouTube channel.
Urologix, Inc., based in Minneapolis, develops, manufactures, markets and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Urologix’s Cooled ThermoTherapy produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva RF Therapy System delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH symptoms. Both of these therapies provide safe, effective and lasting relief of the symptoms and obstruction due to BPH. Prostiva is a registered trademark of Medtronic, Inc., used under license. All other trademarks are the property of Urologix.
If you’d like more information on this topic, please contact Brian Smrdel at (763) 475-7696 or bsmrdel(at)urologix(dot)com or to learn more about Urologix and its products and services, visit their website at http://www.urologix.com.
The Urologix logo is available at http://www.urologix.com/clinicians/resource-library.php.
Urologix Investor Relations Contact
Urologix Media Contact
Mynderse LA, Roehrborn CG, et al. Results of a 5-Year Multicenter Trial of a New Generation Cooled High Energy Transurethral Microwave Thermal Therapy Catheter for BPH. Journal of Urology. Vol. 185, 1804-1811, May 2011
CTC Advance IFU 250348 (http://www.urologix.com/clinicians/resource-library.php)
Hill, B., et al Transurethral Needle Ablation vs TURP for the Treatment of Symptomatic BPH: 5 Year Results of a Prospective, Randomized, Multicenter Clinical Trial, Journal of Urology Vol 171, 2336-2340, June 2004
Data derived from the Prostiva System User Guide 250369-001 (http://www.urologix.com/clinicians/resource-library.php)
Important Safety Information
The Targis System/Cooled ThermoTherapy is indicated to relieve symptoms and obstruction associated with BPH in men with prostatic urethra lengths greater than or equal to 2.5 cm. This treatment is contraindicated for patients with a prostatic urethra <2.5 cm in length as measured from the bladder neck to the verumontanum, with urethral stricture (unable to pass 22F urethroscope), peripheral arterial disease with intermittent claudication or Leriches Syndrome (i.e. claudication of the buttocks or perineum); patients who have undergone pelvic radiation therapy or have implanted active devices, including pacemakers or defibrillators within 2.6 inches (6.5 cm) of the prostatic urethra.
For complete indications, contraindications, and precautions for Prostiva RF Therapy, please refer to the Prostiva System Manual at http://www.urologix.com/clinicians/resource-library.php.
Caution: Federal USA law restricts these devices to sale by or on the order of a physician. For more complete information about the benefits, risks and contraindications associated with Cooled ThermoTherapy and Prostiva RF Therapy, please refer to the product labeling packaged with the device or refer to the System Manual/Instructions for Use found at http://www.urologix.com/clinicians/resource-library.php.